Education
About Us
Working with TipRanks
Follow Us
Inhibitor Therapeutics Inc. (INTI)
OTHER OTC:INTI
INTI Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.04 - $0.14
Previous CloseN/A
Volume30.00
Average Volume (3M)17.54K
Market Cap
$11.36M
Enterprise ValueN/A
Total Cash (Recent Filing)$1.11M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.88
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding172,323,550
10 Day Avg. Volume8,002
30 Day Avg. Volume17,542
Standard Deviation0.42
R-Squared0.00508
Alpha0.06
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-3.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
---
Ownership Overview
30.59% Insiders
―
Mutual Funds
― Other Institutional Investors
69.41% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
INTI FAQ
What was Inhibitor Therapeutics Inc.’s price range in the past 12 months?
Inhibitor Therapeutics Inc. lowest stock price was $0.04 and its highest was $0.14 in the past 12 months.
What is Inhibitor Therapeutics Inc.’s market cap?
Inhibitor Therapeutics Inc.’s market cap is $11.36M.
When is Inhibitor Therapeutics Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Inhibitor Therapeutics Inc.’s earnings last quarter?
Inhibitor Therapeutics Inc. released its earnings results on May 01, 2018. The company reported -$0.003 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.003.
Is Inhibitor Therapeutics Inc. overvalued?
According to Wall Street analysts Inhibitor Therapeutics Inc.’s price is currently Overvalued.
Does Inhibitor Therapeutics Inc. pay dividends?
Inhibitor Therapeutics Inc. does not currently pay dividends.
What is Inhibitor Therapeutics Inc.’s EPS estimate?
Inhibitor Therapeutics Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Inhibitor Therapeutics Inc. have?
Inhibitor Therapeutics Inc. has 172,323,550 shares outstanding.
What happened to Inhibitor Therapeutics Inc.’s price movement after its last earnings report?
Inhibitor Therapeutics Inc. reported an EPS of -$0.003 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Inhibitor Therapeutics Inc.?
Currently, no hedge funds are holding shares in INTI
---
Company Description
Inhibitor Therapeutics Inc.
Inhibitor Therapeutics, Inc. operates as a clinical stage biopharmaceutical company, which discovers, develops and plans to commercialize therapeutics for patients with cancer. It also explores acquiring or licensing therapeutics addressing unmet needs and orphan indications beyond cancer. The company was founded on September 30, 1992 and is headquartered in Tampa, FL.
---
Technical Analysis
---